ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
ChromaDex Corporation

ChromaDex Corporation (CDXC)

2.775
0.015
(0.54%)
Closed July 21 4:00PM
2.775
0.00
(0.00%)
After Hours: 4:05PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
2.775
Bid
2.68
Ask
2.80
Volume
167,019
2.74 Day's Range 2.84
1.25 52 Week Range 4.65
Market Cap
Previous Close
2.76
Open
2.79
Last Trade
6
@
2.77
Last Trade Time
Financial Volume
$ 465,594
VWAP
2.7877
Average Volume (3m)
389,701
Shares Outstanding
75,538,787
Dividend Yield
-
PE Ratio
-42.35
Earnings Per Share (EPS)
-0.07
Revenue
83.57M
Net Profit
-4.94M

About ChromaDex Corporation

ChromaDex Corp is a bioscience company dedicated to healthy aging. The ChromaDex team is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship in... ChromaDex Corp is a bioscience company dedicated to healthy aging. The ChromaDex team is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex's patent portfolio. It delivers Niagen as the sole active ingredient in its consumer product namely, Tru Niagen which is available on Tru Niagen's website and through partnerships with retailers and distributors. Show more

Sector
Medicinal Chems,botanicl Pds
Industry
Medicinal Chems,botanicl Pds
Headquarters
Dover, Delaware, USA
Founded
1970
ChromaDex Corporation is listed in the Medicinal Chems,botanicl Pds sector of the NASDAQ with ticker CDXC. The last closing price for ChromaDex was $2.76. Over the last year, ChromaDex shares have traded in a share price range of $ 1.25 to $ 4.65.

ChromaDex currently has 75,538,787 shares outstanding. The market capitalization of ChromaDex is $208.49 million. ChromaDex has a price to earnings ratio (PE ratio) of -42.35.

CDXC Latest News

ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August

U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to Cenegenics, Clean...

ChromaDex to Join Russell 2000® Index

ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen® supplement, backed by strong financial performance and a robust intellectual property portfolio ChromaDex Corp...

Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)

NR improved the six-minute walking distance and treadmill walking time for those with PAD ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research...

ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)

Clinical study results demonstrated that Niagen IV had no adverse side effects, provided superior tolerability, and a 75% shorter infusion time, with blood NAD+ levels peaking sooner and higher...

ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)

ChromaDex plans to conduct additional studies on NRC in anticipation of filing for an Investigational New Drug Application (IND) for the treatment of AT ChromaDex Corp. (NASDAQ:CDXC), the global...

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial...

ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy-aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief...

ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award

Judges award Niagen for its “high-quality, unparalleled” healthy aging research ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging...

ChromaDex Corporation Reports First Quarter 2024 Financial Results

Total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million and a positive Adjusted EBITDA of $0.7 million for the three months ended March 31, 2024. Reiterated full year...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.115-3.979238754332.893.1052.524376322.80802176CS
40.0752.777777777782.73.1052.3056639762.70748141CS
12-0.665-19.33139534883.443.97992.3053897012.91484485CS
261.34594.05594405591.434.651.363403352.99734847CS
521.04560.40462427751.734.651.252106392.69334244CS
156-6.125-68.82022471918.910.541.152852303.12163723CS
260-1.645-37.21719457014.4223.661.154928888.24892127CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 7.51
(185.55%)
266.26M
AUGXAugmedix Inc
$ 2.27
(147.71%)
24.14M
XCURExicure Inc
$ 0.5351
(76.02%)
14.02M
PSNLPersonalis Inc
$ 3.83
(56.33%)
22.8M
MDBHMDB Capital Holdings LLC
$ 10.675
(37.21%)
126.45k
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M
HYZNHyzon Motors Inc
$ 0.149
(-47.54%)
23.63M
MEDSTRxADE Health Inc
$ 14.92
(-33.45%)
223.27k
SILOSilo Pharma Inc
$ 2.50
(-27.95%)
11.93M
KITTNauticus Robotics Inc
$ 0.0935
(-27.46%)
28.43M
SERVServe Robotics Inc
$ 7.51
(185.55%)
262.73M
NVDANVIDIA Corporation
$ 117.93
(-2.61%)
206.41M
SXTP60 Degrees Pharmaceuticals Inc
$ 0.2602
(5.77%)
202.14M
SQQQProShares UltraPro Short QQQ
$ 8.46
(2.79%)
184.21M
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
119.98M

CDXC Discussion

View Posts
tat4tat tat4tat 1 week ago
Anybody home? Big buy of 29,340 shares at 2.61 ... 76,577.74 bucks.
👍️0
Tiger Money Tiger Money 2 weeks ago
:)
👍️0
Sirpeter Sirpeter 2 weeks ago
Morning bro....this will do like MRVL is doing...my Nov 15 calls here are already making money...I wont tell you what my MRVL calls are doing... might make you sick
👍️0
Sirpeter Sirpeter 3 weeks ago
On Russell 2000 as of today... bidding more $5 Nov. calls
👍️0
Tiger Money Tiger Money 3 weeks ago
Very nice!
👍️0
Sirpeter Sirpeter 3 weeks ago
They are mass marketing a drug suppliment called NIAGEN
There's plenty of reading material under the news heading...my NOV $5 calls just came through by the way...Im excited about this one
👍️0
Sirpeter Sirpeter 3 weeks ago
This will be huge soon
👍️0
Tiger Money Tiger Money 3 weeks ago
Have zero clue about this company. Looks like u bought a nice lotto ticket. I love when those come to fruition
👍️0
Sirpeter Sirpeter 3 weeks ago
Bidding Nov. $5 calls here
👍️0
Sirpeter Sirpeter 1 month ago
...better load back up.maybe in the $2.95 area..will go again
👍️0
Tiger Money Tiger Money 1 month ago
Yes sir!
👍️0
Sirpeter Sirpeter 1 month ago
Nice huh)
👍️0
Tiger Money Tiger Money 1 month ago
Nice call bud
👍️0
Sirpeter Sirpeter 3 months ago
Me of course...this is a profitable business with a national product roll out...financial progress in a week or so
👍️0
tredenwater2 tredenwater2 3 months ago
So…, who is the big buyer of Chromadex? The timing of you “guys” being here “holding big bags” is for a reason, so who is it?
👍️0
Monksdream Monksdream 3 months ago
CDXC under $5
👍️0
Sirpeter Sirpeter 3 months ago
Holding big bags...
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
You couldn’t afford 100 shares
Stop pretending and got nurture your trip bags
👍️0
Sirpeter Sirpeter 3 months ago
Still in this...will explode soon
👍️0
Monksdream Monksdream 3 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
CDXC...BREAK OUT
👍️0
Monksdream Monksdream 4 months ago
CDXC new 52 hi
👍️0
Sirpeter Sirpeter 4 months ago
Beast...almost no shares out
👍️0
Sirpeter Sirpeter 4 months ago
Buying at this level...
👍️0
Sirpeter Sirpeter 4 months ago
..will let you know after your're done licking my balls



👍️0
TrendTrade2016 TrendTrade2016 4 months ago
are you licking your wounds under a rock somewhere on your otc scams..lmao
👍️0
Monksdream Monksdream 4 months ago
CDXC new 52=week hi
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
CDXC...BIO BEASTING...HERE COMES 3 DOLLA
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
MOVE A LONG MAGGOT
👍️0
Sirpeter Sirpeter 4 months ago
Go ahead buy it way up there bird brain
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
CDXC...HERE WE GO
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
CDXC..THE NEXT BIO BEAST READY TO BEAST THROUGH THE STREETS
👍️0
Golden Cross Golden Cross 4 months ago
$3 Next
🤡 1 🤢 1
TrendTrade2016 TrendTrade2016 4 months ago
CDXC,,,NEXT WEEK WEEKLY BLITZ
👍️0
Monksdream Monksdream 4 months ago
CDXC new 52 week hi
👍️0
Monksdream Monksdream 5 months ago
CDXC under $2
👍️0
Monksdream Monksdream 10 months ago
CDXC under $2
👍️0
R9CC R9CC 1 year ago
Law firms looking into it the matter:
https://thebrios.com/chromadex-corporation-investors-investigation/
👍️0
oilin07 oilin07 1 year ago
https://healthnews.com/longevity/longevity-supplements/can-nmn-supplements-cause-cancer/
👍️0
tat4tat tat4tat 2 years ago
Article on Google trending news indicated that this supplement could cause breast cancer leading to brain cancer and death.
👍️0
KMBJN KMBJN 2 years ago
Hey frrol! Good luck with AVXL, and NGENF, each with promising neuroprotective drugs, like NR. Such a tricky space (neurodegeneration in general), but with such a great need and potentially huge reward.

Some anti-amyloid antibody trials have failed in Alzheimer's recently, and some have reported more promising results. I think that gene regulation for amyloid and tau knockdown are also very promising avenues to pursue.

I wonder what the recent news of NMN being taken away as a supplement by FDA will do for NR supplement business, or if/when CDXC will be moving on to the second generation NAD+ boosters, which seem much more potent (and hopefully the IP is really locked away!). Still trying to understand the results and implications of all the lawsuits with Elysium on CDXC's NR business, but it seems like those are all winding down and nothing much good came of it all for CDXC.

https://www.naturalproductsinsider.com/regulatory/trade-groups-react-fda-decision-%CE%B2-nmn-supplements
👍️0
frrol frrol 2 years ago
Saw that article too, this weekend. Finding may be valid. As you point out, a lot of uncertainty, and more research needed. And could be nothing. Good to hear from you! Still got my AVXL. Big readout in 2 weeks....
👍️0
KMBJN KMBJN 2 years ago
How time passes by so quickly. So many ups and downs in biotech, and "the science" is often very slow to play out, or at least for a company to prove they can sell something useful at a profit. Wish I would've learned to sell more on spikes we've had (though I did get my basis out here above $20). Any ways, just a follow up here regarding the possible cancer issue by NR:

insert-text-here

Lastly, we used BiNR to investigate the role of NR uptake in cancer prevalence and metastases formation in triple negative breast cancer (TNBC) animal model. Our results demonstrate that NR supplementation results in a significant increase in cancer prevalence and metastases of TNBC to the brain. These results outline the important role of powerful nutraceuticals like NR in cancer metabolism and the need to personalize their use in certain patient populations.

I don't know how to test this in the real world, except perhaps to do a case control study of those taking NR and looking at incidence of cancer.

It's possible the mouse M TNBC model does not apply to humans.
👍️0
tredenwater2 tredenwater2 2 years ago
Just wanted to post occasionally so the spambots dont crowd out the board. They have a way of crowding everyone else out. This looks like a likely condition or “play” for a buyout. Most likely a 50% premium from here looks ggggggrrreeeeaaat!

Happy Fathers day!
👍️0
tredenwater2 tredenwater2 2 years ago
This supplement could cause peace in the Middle East and it is still going to go down. Wow, talk about an easy takeover with revenue here! Are the 3 “billionaires” buying more?
👍️0
tredenwater2 tredenwater2 3 years ago
Testing one, two,…this stock has flatlined! Wheres the revenue from Wallymart or in the Asian market where this supplement was booming? Are the 3 billionaires still increasing their positions? Must be the Covid curse that killed the rally.

Anecdotally my wife has been on this supplement now for approx 120 days and her endometriosis pain has completely gone away. This is a major blessing and if for no other reason a reason to stay on this supplement for life!
👍️0
someconcerns someconcerns 3 years ago
Yes, agreed. It is however one of those carefully constructed short theses which, while it won't influence a long who has done extensive DD, can easily influence someone who is in this casually. It clearly did not move the markets much this morning.
👍️0
tat4tat tat4tat 3 years ago
Just read it. Wouldnt short after getting product into Walmart.
👍️0
someconcerns someconcerns 3 years ago
Short-oriented blurb on SA today, based on a detailed short piece by some entity called JCap. Can't post it but there was a link in the SA piece.
👍️0
tat4tat tat4tat 3 years ago
Saw Tru Niagen at Walmart the other day.
👍️0

Your Recent History

Delayed Upgrade Clock